Cerity Partners LLC Increases Position in Solventum Co. (NYSE:SOLV)

Cerity Partners LLC grew its position in Solventum Co. (NYSE:SOLV - Free Report) by 27.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 52,719 shares of the company's stock after acquiring an additional 11,337 shares during the quarter. Cerity Partners LLC's holdings in Solventum were worth $3,676,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in SOLV. Biltmore Family Office LLC acquired a new position in Solventum in the 3rd quarter valued at $236,000. Banco Santander S.A. acquired a new stake in Solventum during the 3rd quarter worth $215,000. Thompson Siegel & Walmsley LLC purchased a new stake in shares of Solventum during the third quarter worth $7,719,000. Cypress Capital Group raised its position in shares of Solventum by 9.1% in the third quarter. Cypress Capital Group now owns 20,706 shares of the company's stock valued at $1,444,000 after buying an additional 1,719 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Solventum in the third quarter worth about $227,000.

Solventum Stock Down 1.3 %

Solventum stock traded down $0.97 during mid-day trading on Friday, hitting $71.51. The company's stock had a trading volume of 576,974 shares, compared to its average volume of 1,689,087. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The stock's fifty day moving average is $70.55 and its two-hundred day moving average is $62.60.

Wall Street Analysts Forecast Growth

SOLV has been the subject of several research reports. The Goldman Sachs Group upped their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a "sell" rating in a research note on Monday, August 12th. Wolfe Research initiated coverage on Solventum in a research report on Thursday, September 26th. They issued a "peer perform" rating for the company. BTIG Research assumed coverage on Solventum in a report on Thursday, September 5th. They issued a "neutral" rating for the company. Morgan Stanley boosted their price objective on Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a research note on Monday, November 11th. Finally, Stifel Nicolaus assumed coverage on Solventum in a report on Tuesday, October 8th. They issued a "buy" rating and a $82.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Solventum has an average rating of "Hold" and an average price target of $68.00.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.